Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia

Neurologic Clinics

Volumn 18, Issue 4, 2000, Pages 865-883

  McKeith, Ian G ^a   Burn, David ^b  

^a Wolfson Research Centre   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT; ONDANSETRON;

ALGORITHM; ALZHEIMER DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; MOTOR DYSFUNCTION; NEUROPATHOLOGY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SYNDROME;

EID: 0034518238     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70230-9     Document Type: Article

References (85)

1. Donepezil for dementia with Lewy bodies: A case study
2. Neuropsychiatric aspects of Parkinson's disease
3. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: A community-based study
4. Neuronal basis of mental impairment in parkinsonian syndromes
5. Apolipoprotein E gene in Parkinson's disease with or without dementia
6. Psychological function in dementia with Lewy bodies and senile dementia of Alzheimer's type
7. Idiopathic clouding of consciousness: Do the patients have cortical Lewy body disease?
8. One year follow-up of parkinsonism in dementia with Lewy bodies
9. A prospective study of dementia with Lewy bodies
10. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies
11. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging
12. Lewy bodies in psychiatric patients
13. EEG findings in dementia with Lewy bodies and Alzheimer's disease
14. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease
15. Cognitive defects in Parkinson's disease
16. Paralysis agitans: I. Pathologische Anatomie
17. Motor and cognitive function in Lewy body dementia: Comparison with Alzheimer's and Parkinson's diseases
18. Intravenous levodopa in hallucinating Parkinson's disease patients: High dose challenge does not precipitate hallucinations
19. Clinical and quantitative pathological correlates of dementia with Lewy bodies
20. Hallucinations in Parkinson's disease: Characteristics and associated clinical features
21. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
22. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa
23. Senile dementia of Lewy body type: A review of clinical and pathological features: Implications for treatment
24. Zur pathologie der paralysis agitans und des postenzephalitischen Parkinsonismus
25. Diagnostic assessment and neuropathological correlates of cerebral metabolic changes in dementia with Lewy bodies: PET and postmortem brain studies
26. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
27. Cholinesterase inhibitors in Parkinson's disease
28. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases
29. Structural basis of dementia in neurodegenerative disorders
30. Structural basis of mental impairment in Parkinson's disease
31. Dementia with Lewy bodies: Response of delirium-like features to donepezil
32. Psychiatric features in diffuse Lewy body disease: Findings in 28 pathologically diagnosed cases
33. Diffuse Lewy body disease within the spectrum of Lewy body disease
34. Recent advances in dementia research in Japan: Non-Alzheimer type degenerative dementias
35. Diffuse type of Lewy body disease: Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: A new disease?
36. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly
37. Diffuse Lewy body disease: Correlative neuropathology using anti-ubiquitin immunocytochemistry
38. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson's disease, and dementia with Lewy bodies
39. Pathologically diagnosed diffuse Lewy body disease and Parkinson's disease: Do the parkinsonian features differ?
40. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease
41. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample
42. Depression in Parkinson's disease: A biological and organic viewpoint
43. Putative clinical and genetic antecedents of dementia associated with Parkinson's disease
44. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
45. Dementia with Lewy bodies: Clinical and pathological diagnosis
46. Neuroleptic sensitivity to risperidone in Lewy body dementia
47. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies
48. Management of the noncognitive symptoms of Lewy body dementia
49. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop
50. Rivastigmine in the treatment of dementia with Lewy bodies
51. Apolipoprotein E genotyping in Alzheimer's disease
52. Diagnosing dementia with Lewy bodies
53. Report of the second dementia with Lewy body international workshop
54. Operational criteria for senile dementia of Lewy body type (SDLT)
55. Prospective study of relations between cortical Lewy bodies, poor eyesight and hallucinations in Alzheimer's disease
56. Prospective evaluation of diagnostic criteria for dementia with Lewy bodies
57. Dementia with Lewy bodies: Reliability and validity of clinical and pathologic criteria
58. Extrapyramidisation in Alzheimer's disease: Prevalence, psychiatric and neuropsychological correlates
59. Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias
60. Psychotic symptoms in Parkinson's disease patients with dementia
61. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease
62. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadrapesis in flexion
63. Diagnosing Lewy body disease: Accuracy of clinical criteria in detecting Lewy body pathology
64. Hallucinations, sleep fragmentation, and altered dream phenomenon in Parkinson's disease
65. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer's disease
66. Evidence of monaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia
67. Altered consciousness and transmitter signalling in Lewy body dementia
68. What is the neuropathological basis of dementia associated with Lewy bodies?
69. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: Rostrocaudal distribution
70. Dopamine D 2 receptors in demented patients with severe neuroleptic sensitivity
71. Regional cerebral blood flow in patients with dementia with Lewy bodies. Neurobiol Aging
72. A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types
73. Neuropsychological aspects of Lewy body dementia
74. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease
75. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
76. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
77. Dementia with Lewy bodies: Histochemical aspects of differential diagnosis
78. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia
79. Neuropsychological performance in Lewy body dementia and Alzheimer's disease
80. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies
81. Olanzapine in dementia with Lewy bodies: A clinical study
82. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
83. Concentric hyaline inclusion body formation in mental disease: Analysis of twenty-seven cases
84. Ondansetron for hallucinosis in advanced Parkinson's disease